Van Cutsem, E <br/><br/>
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Jan 2015 
 - 149-156 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdu496  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Capecitabine<br/>Deoxycytidine--adverse effects<br/>Disease-Free Survival<br/>Docetaxel<br/>Drug Administration Schedule<br/>Female<br/>Fluorouracil--adverse effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Organoplatinum Compounds--adverse effects<br/>Oxaliplatin<br/>Prospective Studies<br/>Stomach Neoplasms--drug therapy<br/>Taxoids--adverse effects<br/>Treatment Outcome